Report Detail
Global Age Related Macular Degeneration Drug Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
- RnM4656430 |
- 19 March, 2026 |
- Global |
- 75 Pages |
- GIR |
- Pharma & Healthcare
According to our (Global Info Research) latest study, the global Age Related Macular Degeneration Drug market size was valued at US$ 9380 million in 2025 and is forecast to a readjusted size of US$ 13820 million by 2032 with a CAGR of 5.8% during review period.
Age Related Macular Degeneration Drugs (AMD drugs) are therapeutic solutions developed to address vision loss or blurriness caused by degeneration in the macular region among the elderly. These drugs primarily act through mechanisms such as inhibiting abnormal blood vessel formation, antioxidant protection, inflammation modulation, or improvement of retinal cell metabolism to slow down or reverse the progression of macular degeneration. With the acceleration of population aging and growing awareness of eye health, AMD drugs hold significant clinical value and have become a key focus in ophthalmic drug development and market strategy.In 2024, global Age Related Macular Degeneration Drugs production reached approximately 7.87 million units, with an average global market price of around US$ 1100 perunit.The average gross profit margin of this product is 85%.
The AMD drug market is facing multiple development opportunities. Firstly, the continuous growth of the aging population globally expands the patient base, providing long-term demand support. Secondly, advances in ophthalmic medical technology and improved early diagnostic capabilities facilitate earlier intervention, driving drug usage frequency and market penetration. Additionally, increased public health awareness, the popularization of vision protection concepts, and expanded insurance coverage create new growth drivers for the AMD drug market. Finally, innovation by multinational pharmaceutical companies and local R&D institutions in biopharmaceutical technologies, targeted therapies, and gene therapy accelerates technological support and diversification of products in the market.
Despite significant market potential, AMD drug development faces challenges and risks. Long R&D cycles, high investment costs, and complex clinical trials prolong the time to market for new drugs. Uncertainty in drug efficacy and safety, including potential resistance or adverse reactions in some patients, increases clinical application difficulty. Stricter regulatory policies and differences in drug approval processes across countries may also constrain market expansion. Moreover, competition from generics and pricing pressures pose commercialization risks for high-end innovative drugs.
Downstream demand for AMD drugs shows diversified trends. With an increasing aging population and the popularization of chronic eye disease management concepts, patient demand for early intervention and long-term treatment continues to grow. The rise of ophthalmic specialty hospitals, community healthcare centers, and telemedicine platforms has also expanded drug prescription channels. Patients’ preference for personalized and targeted treatment options drives demand for innovative drugs and combination therapies. Furthermore, with optimized insurance policies and improved social security systems, downstream market affordability and accessibility steadily increase, supporting continued penetration of AMD drugs.
The upstream raw materials for AMD drugs mainly include biopharmaceutical agents, anti-VEGF molecules, protein engineering materials, and small molecule chemical precursors. The stability of raw material supply directly affects drug production and cost control, especially given the high manufacturing complexity of high-purity proteins and bioactive components. Upstream factors such as production technology levels, supply chain diversity, and international trade policies significantly influence drug R&D and manufacturing efficiency. With the improvement of the biopharmaceutical industry chain, standardization and quality control of raw materials have gradually increased, providing support for the reliable supply of AMD drugs.
This report is a detailed and comprehensive analysis for global Age Related Macular Degeneration Drug market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Age Related Macular Degeneration Drug market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (USD/Unit), 2021-2032
Global Age Related Macular Degeneration Drug market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (USD/Unit), 2021-2032
Global Age Related Macular Degeneration Drug market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (USD/Unit), 2021-2032
Global Age Related Macular Degeneration Drug market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (USD/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Age Related Macular Degeneration Drug
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Age Related Macular Degeneration Drug market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Regeneron Pharmaceuticals, Bayer HealthCare, Novartis, Roche, Kanghong Pharma, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Age Related Macular Degeneration Drug market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Lucentis
Eylea
Avastin
Others
Market segment by Clinical Type
Wet ADM
Dry ADM
Market segment by Administration Route
Intravitreal injection
Oral Administration
Topical Eye Drops
Other
Market segment by Application
Hospitals
Clinics
Others
Major players covered
Regeneron Pharmaceuticals
Bayer HealthCare
Novartis
Roche
Kanghong Pharma
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Age Related Macular Degeneration Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Age Related Macular Degeneration Drug, with price, sales quantity, revenue, and global market share of Age Related Macular Degeneration Drug from 2021 to 2026.
Chapter 3, the Age Related Macular Degeneration Drug competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Age Related Macular Degeneration Drug breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Age Related Macular Degeneration Drug market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Age Related Macular Degeneration Drug.
Chapter 14 and 15, to describe Age Related Macular Degeneration Drug sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
- 1.3.1 Overview: Global Age Related Macular Degeneration Drug Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 Lucentis
- 1.3.3 Eylea
- 1.3.4 Avastin
- 1.3.5 Others
- 1.4 Market Analysis by Clinical Type
- 1.4.1 Overview: Global Age Related Macular Degeneration Drug Consumption Value by Clinical Type: 2021 Versus 2025 Versus 2032
- 1.4.2 Wet ADM
- 1.4.3 Dry ADM
- 1.5 Market Analysis by Administration Route
- 1.5.1 Overview: Global Age Related Macular Degeneration Drug Consumption Value by Administration Route: 2021 Versus 2025 Versus 2032
- 1.5.2 Intravitreal injection
- 1.5.3 Oral Administration
- 1.5.4 Topical Eye Drops
- 1.5.5 Other
- 1.6 Market Analysis by Application
- 1.6.1 Overview: Global Age Related Macular Degeneration Drug Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.6.2 Hospitals
- 1.6.3 Clinics
- 1.6.4 Others
- 1.7 Global Age Related Macular Degeneration Drug Market Size & Forecast
- 1.7.1 Global Age Related Macular Degeneration Drug Consumption Value (2021 & 2025 & 2032)
- 1.7.2 Global Age Related Macular Degeneration Drug Sales Quantity (2021-2032)
- 1.7.3 Global Age Related Macular Degeneration Drug Average Price (2021-2032)
2 Manufacturers Profiles
- 2.1 Regeneron Pharmaceuticals
- 2.1.1 Regeneron Pharmaceuticals Details
- 2.1.2 Regeneron Pharmaceuticals Major Business
- 2.1.3 Regeneron Pharmaceuticals Age Related Macular Degeneration Drug Product and Services
- 2.1.4 Regeneron Pharmaceuticals Age Related Macular Degeneration Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.1.5 Regeneron Pharmaceuticals Recent Developments/Updates
- 2.2 Bayer HealthCare
- 2.2.1 Bayer HealthCare Details
- 2.2.2 Bayer HealthCare Major Business
- 2.2.3 Bayer HealthCare Age Related Macular Degeneration Drug Product and Services
- 2.2.4 Bayer HealthCare Age Related Macular Degeneration Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.2.5 Bayer HealthCare Recent Developments/Updates
- 2.3 Novartis
- 2.3.1 Novartis Details
- 2.3.2 Novartis Major Business
- 2.3.3 Novartis Age Related Macular Degeneration Drug Product and Services
- 2.3.4 Novartis Age Related Macular Degeneration Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.3.5 Novartis Recent Developments/Updates
- 2.4 Roche
- 2.4.1 Roche Details
- 2.4.2 Roche Major Business
- 2.4.3 Roche Age Related Macular Degeneration Drug Product and Services
- 2.4.4 Roche Age Related Macular Degeneration Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.4.5 Roche Recent Developments/Updates
- 2.5 Kanghong Pharma
- 2.5.1 Kanghong Pharma Details
- 2.5.2 Kanghong Pharma Major Business
- 2.5.3 Kanghong Pharma Age Related Macular Degeneration Drug Product and Services
- 2.5.4 Kanghong Pharma Age Related Macular Degeneration Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.5.5 Kanghong Pharma Recent Developments/Updates
3 Competitive Environment: Age Related Macular Degeneration Drug by Manufacturer
- 3.1 Global Age Related Macular Degeneration Drug Sales Quantity by Manufacturer (2021-2026)
- 3.2 Global Age Related Macular Degeneration Drug Revenue by Manufacturer (2021-2026)
- 3.3 Global Age Related Macular Degeneration Drug Average Price by Manufacturer (2021-2026)
- 3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Age Related Macular Degeneration Drug by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Age Related Macular Degeneration Drug Manufacturer Market Share in 2025
- 3.4.3 Top 6 Age Related Macular Degeneration Drug Manufacturer Market Share in 2025
- 3.5 Age Related Macular Degeneration Drug Market: Overall Company Footprint Analysis
- 3.5.1 Age Related Macular Degeneration Drug Market: Region Footprint
- 3.5.2 Age Related Macular Degeneration Drug Market: Company Product Type Footprint
- 3.5.3 Age Related Macular Degeneration Drug Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
- 4.1 Global Age Related Macular Degeneration Drug Market Size by Region
- 4.1.1 Global Age Related Macular Degeneration Drug Sales Quantity by Region (2021-2032)
- 4.1.2 Global Age Related Macular Degeneration Drug Consumption Value by Region (2021-2032)
- 4.1.3 Global Age Related Macular Degeneration Drug Average Price by Region (2021-2032)
- 4.2 North America Age Related Macular Degeneration Drug Consumption Value (2021-2032)
- 4.3 Europe Age Related Macular Degeneration Drug Consumption Value (2021-2032)
- 4.4 Asia-Pacific Age Related Macular Degeneration Drug Consumption Value (2021-2032)
- 4.5 South America Age Related Macular Degeneration Drug Consumption Value (2021-2032)
- 4.6 Middle East & Africa Age Related Macular Degeneration Drug Consumption Value (2021-2032)
5 Market Segment by Type
- 5.1 Global Age Related Macular Degeneration Drug Sales Quantity by Type (2021-2032)
- 5.2 Global Age Related Macular Degeneration Drug Consumption Value by Type (2021-2032)
- 5.3 Global Age Related Macular Degeneration Drug Average Price by Type (2021-2032)
6 Market Segment by Application
- 6.1 Global Age Related Macular Degeneration Drug Sales Quantity by Application (2021-2032)
- 6.2 Global Age Related Macular Degeneration Drug Consumption Value by Application (2021-2032)
- 6.3 Global Age Related Macular Degeneration Drug Average Price by Application (2021-2032)
7 North America
- 7.1 North America Age Related Macular Degeneration Drug Sales Quantity by Type (2021-2032)
- 7.2 North America Age Related Macular Degeneration Drug Sales Quantity by Application (2021-2032)
- 7.3 North America Age Related Macular Degeneration Drug Market Size by Country
- 7.3.1 North America Age Related Macular Degeneration Drug Sales Quantity by Country (2021-2032)
- 7.3.2 North America Age Related Macular Degeneration Drug Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)
8 Europe
- 8.1 Europe Age Related Macular Degeneration Drug Sales Quantity by Type (2021-2032)
- 8.2 Europe Age Related Macular Degeneration Drug Sales Quantity by Application (2021-2032)
- 8.3 Europe Age Related Macular Degeneration Drug Market Size by Country
- 8.3.1 Europe Age Related Macular Degeneration Drug Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Age Related Macular Degeneration Drug Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Age Related Macular Degeneration Drug Sales Quantity by Type (2021-2032)
- 9.2 Asia-Pacific Age Related Macular Degeneration Drug Sales Quantity by Application (2021-2032)
- 9.3 Asia-Pacific Age Related Macular Degeneration Drug Market Size by Region
- 9.3.1 Asia-Pacific Age Related Macular Degeneration Drug Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Age Related Macular Degeneration Drug Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)
10 South America
- 10.1 South America Age Related Macular Degeneration Drug Sales Quantity by Type (2021-2032)
- 10.2 South America Age Related Macular Degeneration Drug Sales Quantity by Application (2021-2032)
- 10.3 South America Age Related Macular Degeneration Drug Market Size by Country
- 10.3.1 South America Age Related Macular Degeneration Drug Sales Quantity by Country (2021-2032)
- 10.3.2 South America Age Related Macular Degeneration Drug Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Age Related Macular Degeneration Drug Sales Quantity by Type (2021-2032)
- 11.2 Middle East & Africa Age Related Macular Degeneration Drug Sales Quantity by Application (2021-2032)
- 11.3 Middle East & Africa Age Related Macular Degeneration Drug Market Size by Country
- 11.3.1 Middle East & Africa Age Related Macular Degeneration Drug Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Age Related Macular Degeneration Drug Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)
12 Market Dynamics
- 12.1 Age Related Macular Degeneration Drug Market Drivers
- 12.2 Age Related Macular Degeneration Drug Market Restraints
- 12.3 Age Related Macular Degeneration Drug Trends Analysis
- 12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
- 13.1 Raw Material of Age Related Macular Degeneration Drug and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Age Related Macular Degeneration Drug
- 13.3 Age Related Macular Degeneration Drug Production Process
- 13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
- 14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
- 14.2 Age Related Macular Degeneration Drug Typical Distributors
- 14.3 Age Related Macular Degeneration Drug Typical Customers
15 Research Findings and Conclusion
16 Appendix
- 16.1 Methodology
- 16.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on Age Related Macular Degeneration Drug. Industry analysis & Market Report on Age Related Macular Degeneration Drug is a syndicated market report, published as Global Age Related Macular Degeneration Drug Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Age Related Macular Degeneration Drug market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
